Sex | Age, yrs | Observed LA ASAS-COMOSPA | Expected General Population Prevalence (%) | SRR (CI 95%) | Global ASAS-COMOSPA | ||
---|---|---|---|---|---|---|---|
n | (%) | n | (%) | ||||
Men | 20–39 | 0 | 0 | 0.41 | — | 4 | 0.3 |
40–44 | 0 | 0 | 0.76 | — | 2 | 0.6 | |
45–49 | 0 | 0 | 1.29 | — | 5 | 1.6 | |
50–54 | 1 | 5.0 | 2.39 | 2.0 | 8 | 3.0 | |
55–59 | 1 | 7.6 | 4.11 | 1.8 | 9 | 3.9 | |
60–64 | 1 | 7.1 | 6.49 | 1.0 | 9 | 5.4 | |
65–70 | 1 | 8.3 | 9.28 | 0.8 | 13 | 11.3 | |
≥ 70 | 1 | 7.6 | 15.17 | 0.5 | 27 | 21.9 | |
Total men | 5 | 2.0 | 2.41 | 0.8 (0.3–1.9) | 77 | 2.9 | |
Women | 20–39 | 0 | 0 | 0.54 | — | 6 | 1.2 |
40–44 | 0 | 0 | 1.91 | — | 3 | 1.6 | |
45–49 | 1 | 4.3 | 2.70 | 1.5 | 4 | 2.2 | |
50–54 | 2 | 15.3 | 3.53 | 4.3 | 11 | 6.0 | |
55–59 | 2 | 13.3 | 4.49 | 2.9 | 6 | 4.6 | |
60–64 | 1 | 8.3 | 5.90 | 1.4 | 10 | 10.0 | |
65–70 | 0 | 0 | 6.98 | — | 4 | 4.8 | |
≥ 70 | 0 | 0 | 9.57 | — | 7 | 10.7 | |
Total women | 6 | 4.2 | 2.67 | 1.5 (0.7–3.4) | 51 | 3.6 | |
Total (men/women) | 11 | 2.8 | 2.6 | 1.0 (0.6–1.9) | 128 | 3.2 |
LA: Latin America; n: number with a diagnosis of malignancies in each sex and age group; ASAS-COMOSPA: Assessment of SpondyloArthritis international Society of COMOrbidities in SpA; SpA: spondyloarthritis; SRR: standardized risk ratio.